Durable polymer everolimus-eluting stents: history, current status and future prospects

References

• Meier B, Bachmann D, Lüscher TF. 25 Years of coronary angioplasty: almost a fairy tale [1]. Lancet. 2003;361(9356):527.
   PubMed Web of Science ®Google Scholar
• Gruentzig A, Turina M, Krayenbuehl C, et al. Percutaneous transluminal dilatation of coronary artery stenosis. Thorac Cardiovasc Surg. 1979;27(3):199–201.
   PubMed Web of Science ®Google Scholar
• Garg S, Serruys PW. Coronary stents: current status. J Am Coll Cardiol. 2010;56(10 SUPPL.):S1–42.
   PubMed Web of Science ®Google Scholar
• Chandrasekar B, Tanguay JF. Platelets and restenosis. J Am Coll Cardiol. 2000;35(3):555–562.
   PubMed Web of Science ®Google Scholar
• Yoshida Y, Mitsumata M, Ling G, et al. Migration of medial smooth muscle cells to the intima after balloon injury. Ann N Y Acad Sci. 1997;811:459–470.
   PubMed Web of Science ®Google Scholar
• Sigwart U, Puel J, V M, et al. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med. 1987;316:701–706.
   PubMed Web of Science ®Google Scholar
• de Feyter PJ, de Jaegere P, P T, et al. Incidence, predictors, and management of acute coronary occlusion after coronary angioplasty. Am Heart J. 1994;127(3):643–651.
   PubMed Web of Science ®Google Scholar
• Serruys PW, de Jaegere P, K F, et al. A comparison of balloon-expandable-stent im- plantation with balloon angioplasty in patients with coronary artery disease. BENESTENT study group. N Engl J Med. 1994;331:489–495.
   PubMed Web of Science ®Google Scholar
• Fischman DL, Leon MB, B D, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent restenosis study investigators. N Engl J Med. 1994;331:496–501.
   PubMed Web of Science ®Google Scholar
• Serruys PW, Strauss BH, B K. Angiographic follow-up after placement of a self-expanding coronary-artery stent. N Engl J Med. 1991;324:13–17.
   PubMed Web of Science ®Google Scholar
• Hoffmann R, Mintz GS, D G, et al. Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. Circulation. 1996;94:1247–1254.
   PubMed Web of Science ®Google Scholar
• Kastrati A, Schomig A, Dirschinger J, et al. Increased risk of restenosis after placement of gold-coated stents. Circulation. 2001;104(5):2478–2483.
   PubMed Web of Science ®Google Scholar
• Ryu SK, Mahmud E, Tsimikas S. Estrogen-eluting stents. J Cardiovasc Transl Res. 2009;2(3):240–244.
   PubMed Web of Science ®Google Scholar
• Morice MC, Serruys PW, S J, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346(23):1773–1780.
   PubMed Web of Science ®Google Scholar
• Stone GW, Ellis SG, C D, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004;350:221–231.
   PubMed Web of Science ®Google Scholar
• Spaulding C, Daemen J, Boersma E, et al. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med. 2007;356:989–997.
   PubMed Web of Science ®Google Scholar
• Stettler C, Wandel S, Allemann S, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet. 2007;370(9591):937–948.
   PubMed Web of Science ®Google Scholar
• Kastrati A, Mehilli J, Pache J. Analysis of 14 trials comparing Sirolimus-Eluting stents with bare-metal Stents. Surv Anesthesiol. 2008;52(4):175–176.
   Google Scholar
• McFadden EP, Stabile E, Regar E, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet. 2004;364(9444):1519–1521.
   PubMed Web of Science ®Google Scholar
• Lagerqvist B, Carlsson J, Fröbert O, et al. Stent thrombosis in Sweden a report from the Swedish coronary angiography and angioplasty registry. Circ Cardiovasc Interv. 2009;2(5):401–408.
   PubMed Web of Science ®Google Scholar
• Laskey WK, Yancy CW, Maisel WH. Thrombosis in coronary drug-eluting stents: report from the meeting of the circulatory system medical devices advisory panel of the food and drug administration center for devices and radiologic health, december 7-8, 2006. Circulation. 2007;115(17):2352–2357.
   PubMed Web of Science ®Google Scholar
• Pinto Slottow TL, Steinberg DH, Roy PK. Observations and outcomes of definite and probable drug-eluting stent thrombosis seen at a single hospital in a four-year period. Am J Cardiol. 2008;102:298–303.
   PubMed Web of Science ®Google Scholar
• James SK, Wallentin L, L B. The SCAAR-scare in perspective. EuroIntervention. 2009;5:501–504.
   PubMed Web of Science ®Google Scholar
• Nakazawa G, Ladich E, Finn AV, et al. Pathophysiology of vascular healing and stent mediated arterial injury. EuroIntervention. 2008;4(Suppl):C:7–10.
   PubMedGoogle Scholar
• Xu YW, Wei YD, T K. Multi-link vision and minivision stent registry in Asian patients with coronary artery disease: a prospective, multi-center study. Chin Med J (Engl). 2007;120:1093–1096.
   PubMed Web of Science ®Google Scholar
• Ortolani P, Marzocchi A, Marrozzini C, et al. Randomized comparative trial of a thin-strut bare metal cobalt-chromium stent versus a sirolimus-eluting stent for coronary revascularization. Catheter Cardiovasc Interv. 2007;69(6):790–798.
   PubMed Web of Science ®Google Scholar
• Mani G, Feldman MD, Patel D, et al. Coronary stents: A materials perspective. Biomaterials. 2007;28(9):1689–1710.
   PubMed Web of Science ®Google Scholar
• Hoffmann R, Mintz GS, Haager PK, et al. Relation of stent design and stent surface material to subsequent in-stent intimal hyperplasia in coronary arteries determined by intravascular ultrasound. Am J Cardiol. 2002;89(12):1360–1364.
   PubMed Web of Science ®Google Scholar
• Hospital BC, Health B, Trust SC, et al. Clinical impact of stent design. Interventional Cardiology Review. 2014;9(2):89–93.
   Google Scholar
• Kereiakes DJ, Cox DA, Hermiller JB, et al. Usefulness of a cobalt chromium coronary stent alloy. Am J Cardiol. 2003;92(4):463–466.
   PubMed Web of Science ®Google Scholar
• Schuler PW, Sedrani R, C S. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation. 1997;64:36–42.
   PubMed Web of Science ®Google Scholar
• Ding N, Pacetti SD, Tang FW, et al. XIENCE VTM stent design and rationale. J Interv Cardiol. 2009;22(SUPPL. 1):18–27.
   Google Scholar
• Mulvihill JN, Faradji A, Oberling F, et al. Surface passivation by human albumin of plasmaperesis circuits reduces platelet accumulation and thrombus formation. Experimental and clinical studies. J Biomed Mater Res. 1990;24(2):155–163.
   PubMed Web of Science ®Google Scholar
• Pedrini L, Dondi M, Magagnoli A, et al. Evaluation of thrombogenicity of fluoropassivated polyester patches following carotid endarterectomy. Ann Vasc Surg. 2001;15(6):679–683.
   PubMed Web of Science ®Google Scholar
• Serruys PW, Ong AT, P J. A randomized comparison of a durable polymer everolimus-eluting stent with a bare metal coronary stent: the first SPIRIT first trial. EuroIntervention. 2005;1:58–65.
   PubMedGoogle Scholar
• Tsuchida K, Piek JJ, N F. One-year results of a durable polymer everolimus-eluting stent in de novo coronary narrowings (the SPIRIT FIRST trial). EuroIntervention. 2005;1:266–272.
   PubMedGoogle Scholar
• Serruys PW, Ruygrok P, N J. A randomized comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: the SPIRIT II trial. EuroIntervention. 2006;2:286–294.
   PubMedGoogle Scholar
• Claessen BE, Beijk MA, Legrand V, et al. Two-year clinical, angiographic, and intravascular ultrasound follow-up of the XIENCE V everolimus-eluting stent in the treatment of patients with de novo native coronary artery lesions the SPIRIT II trial. Circ Cardiovasc Interv. 2009;2(4):339–347.
   PubMed Web of Science ®Google Scholar
• Stone GW, Midei M, Newman W, et al. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the clinical evaluation of the xience V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery l. Circulation. 2009;119(5):680–686.
   PubMed Web of Science ®Google Scholar
• GW S, R A, N W. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl Med. 2010;362:1663–1674.
   PubMed Web of Science ®Google Scholar
• Grube E, Chevalier B, Smits P, et al. The SPIRIT v study. JACC Cardiovasc Interv. 2011;4(2):168–175.
   PubMed Web of Science ®Google Scholar
• Park KW, Kang SH, Kang HJ, et al. A randomized comparison of platinum chromium-based everolimus-eluting stents versus cobalt chromium-based zotarolimus-eluting stents in all-comers receiving percutaneous coronary intervention: HOST-ASSURE noninferiority trial. J Am Coll Cardiol. 2014;63(25 PART A):2805–2816.
   PubMed Web of Science ®Google Scholar
• Kim CH, Park KW, Kang J, et al. Long-term comparison of platinum chromium everolimus-eluting stent vs. cobalt chromium zotarolimus-eluting stent: 3-year outcomes from the HOST–ASSURE randomized clinical trial. Circ J. 2019;83(7):1489–1497.
   PubMed Web of Science ®Google Scholar
• Kereiakes DJ, Meredith IT, Windecker S, et al. Efficacy and safety of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent. Circ Cardiovasc Interv. 2015;8(4):1–8.
   Web of Science ®Google Scholar
• El-Hayek G, Bangalore S, Casso Dominguez A, et al. Meta-analysis of randomized clinical trials comparing biodegradable polymer drug-eluting stent to second-generation durable polymer drug-eluting stents. JACC Cardiovasc Interv. 2017;10(5):462–473.
   PubMed Web of Science ®Google Scholar
• Onuma Y, Kukreja N, Piazza N, et al. The everolimus-eluting stent in real-world patients. 6-month follow-up of the X-Search (Xience V Stent evaluated at Rotterdam Cardiac Hospital) registry. J Am Coll Cardiol. 2009;54(3):269–276.
   PubMed Web of Science ®Google Scholar
• Sabate M, Cequier A, Iñiguez A, et al. Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial. Lancet. 2012;380(9852):1482–1490.
   PubMed Web of Science ®Google Scholar
• Sabaté M, Brugaletta S, Cequier A, et al., Clinical outcomes in patients with ST-segment elevation myocardial infarction treated with everolimus-eluting stents versus bare-metal stents (EXAMINATION): 5-year results of a randomised trial. Lancet. 387(10016): 357–366. 2016.
   PubMed Web of Science ®Google Scholar
• Sabaté M, Cequier A, Iñiguez A, et al. Rationale and design of the EXAMINATION trial: a randomised comparison between everolimus-eluting stents and cobalt-chromium bare-metal stents in ST-elevation myocardial infarction. EuroIntervention. 2011;7(8):977–984. 30AD.
   PubMed Web of Science ®Google Scholar
• Sen H, Lam MK, Löwik MM, et al. Clinical events and patient-reported chest pain in all-comers treated with resolute integrity and promus element stents: 2-year follow-up of the Dutch Peers (durable polymer-based stent challenge of Promus element versus resolute integrity) randomized tri. JACC Cardiovasc Interv. 2015;8(7):889–899.
   PubMed Web of Science ®Google Scholar
• Zocca P, Kok MM, Tandjung K, et al. 5-year outcome following randomized treatment of all-comers with Zotarolimus-Eluting resolute integrity and everolimus-eluting PROMUS element coronary stents: final report of the Dutch Peers (TWENTE II) trial. JACC Cardiovasc Interv. 2018;11(5):462–469.
   PubMed Web of Science ®Google Scholar
• SH H, PC S, Brouwer J. Long-term follow-up of second-generation everolimus-eluting stents versus first-generation sirolimus-eluting stents in acute myocardial infarction: three-year results of the XAMI trial. EuroIntervention. 2015 Mar;10(11):1280–1283.
   Google Scholar
• Di Lorenzo E, Sauro R, Capasso M, et al. Long-term results of the randomized comparison of everolimus-eluting stents and sirolimus-eluting stent in patients with ST elevation myocardial infarction (RACES-MI trial). Int J Cardiol. 2016;202:177–182.
   PubMed Web of Science ®Google Scholar
• Palmerini T, Biondi-Zoccai G, Della Riva D, et al. Clinical outcomes with drug-eluting and bare-metal stents in patients with ST-segment elevation myocardial infarction: evidence from a comprehensive network meta-analysis. J Am Coll Cardiol. 2013;62(6):496–504.
   PubMed Web of Science ®Google Scholar
• Bangalore S, Amoroso N, Fusaro M, et al. Outcomes with various drug-eluting or bare metal stents in patients with st-segment-elevation myocardial infarction: A mixed treatment comparison analysis of trial level data from 34 068 patient-years of follow-up from randomized trials. Circ Cardiovasc Interv. 2013;6(4):378–390.
   PubMed Web of Science ®Google Scholar
• Chichareon P, Modolo R, Collet C, et al. Efficacy and safety of stents in ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2019;74(21):2572–2584.
   PubMed Web of Science ®Google Scholar
• Iglesias JF, Muller O, Heg D, et al., Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial. Lancet. 394(10205): 1243–1253. 2019.
   PubMed Web of Science ®Google Scholar
• Goraya TY, Leibson CL, Palumbo PJ, et al. Coronary atherosclerosis in diabetes mellitus: a population-based autopsy study. J Am Coll Cardiol. 2002;40:946–953.
   PubMed Web of Science ®Google Scholar
• Stein B, Weintraub WS, Gebhart SP, et al. Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. Circulation. 1995;91:979–989.
   PubMed Web of Science ®Google Scholar
• Iwasaki M, Otake H, Shinke T, et al. Vascular responses in patients with and without diabetes mellitus after everolimus-eluting stent implantation – optical coherence tomography study –. Circ J. 2014;78(9):2188–2196.
   PubMed Web of Science ®Google Scholar
• Maeng M, Baranauskas A, Christiansen EH, et al. A 10-month angiographic and 4-year clinical outcome of everolimus-eluting versus sirolimus-eluting coronary stents in patients with diabetes mellitus (the diabedES IV randomized angiography trial). Catheter Cardiovasc Interv. 2015;86(7):1161–1167.
   PubMed Web of Science ®Google Scholar
• Kaul U, Bangalore S, Seth A, et al. Paclitaxel-eluting versus everolimus-eluting coronary stents in diabetes. N Engl J Med. 2015;373(18):1709–1719.
   PubMed Web of Science ®Google Scholar
• Jimenez-Quevedo P, Brugaletta S, Cequier A, et al. Long-term impact of diabetes in patients with ST-segment elevation myocardial infarction: insights from the examination randomized trial. Catheter Cardiovasc Interv. 2019 Dec 1;94(7):917–925.
   Web of Science ®Google Scholar
• Iglesias JF, Heg D, Roffi M, et al. Five-year outcomes in patients with diabetes mellitus treated with biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents. J Am Heart Assoc. 2019;8;(22):e013607.
   PubMed Web of Science ®Google Scholar
• Kereiakes DJ, Meredith IT, Masotti M, et al. Safety and efficacy of a bioabsorbable polymer-coated, everolimus-eluting coronary stent in patients with diabetes: the EVOLVE II diabetes substudy. EuroIntervention J Eur Collab with Work Gr Interv Cardiol Eur Soc Cardiol. 2017;12(16):1987–1994.
   Google Scholar
• Romaguera R, Gómez-Hospital JA, Gomez-Lara J, et al. A randomized comparison of reservoir-based polymer-free amphilimus-eluting stents versus everolimus-eluting stents with durable polymer in patients with diabetes mellitus the reservoir clinical trial. JACC Cardiovasc Interv. 2016;9(1):42–50.
   PubMed Web of Science ®Google Scholar
• Morice MC. Stenting for small coronary vessels. J Invasive Cardiol. 2003;15(7):377–379.
   PubMedGoogle Scholar
• Hermiller JB, Fergus T, Pierson W, et al. Clinical and angiographic comparison of everolimus-eluting and paclitaxel-eluting stents in small coronary arteries: A post hoc analysis of the SPIRIT III randomized trial. Am Heart J. 2009;158(6):1005–1010.
   PubMed Web of Science ®Google Scholar
• Joner M, Nakazawa G, Finn AV, et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol. 2008;52(5):333–342.
   PubMed Web of Science ®Google Scholar
• Tama N, Uzui H, Horita Y, et al. Initial and late efficacy of everolimus-eluting stents for small and non-small coronary lesions from evaluating delayed late loss study. Heart Vessels. 2017;32(12):1415–1423.
   PubMed Web of Science ®Google Scholar
• Yano H, Horinaka S, Ishikawa M, et al. Efficacy of everolimus-eluting stent implantation in patients with small coronary arteries (≤2.5 mm): outcomes of 3-year clinical follow-up. Heart Vessels. 2017;32(7):796–803.
   PubMed Web of Science ®Google Scholar
• Teirstein PS, Meredith IT, Feldman RL, et al. Two-year safety and effectiveness of the platinum chromium everolimus-eluting stent for the treatment of small vessels and longer lesions. Catheter Cardiovasc Interv. 2015;85(2):207–215.
   PubMed Web of Science ®Google Scholar
• Iglesias JF, Heg D, Roffi M, et al. Long-term effect of ultrathin-strut versus thin-strut drug-eluting stents in patients with small vessel coronary artery disease undergoing percutaneous coronary intervention: a subgroup analysis of the bioscience randomized trial. Circ Cardiovasc Interv. 2019;12;(8):e008024.
   PubMed Web of Science ®Google Scholar
• Lefèvre T, Haude M, Neumann FJ, et al. Comparison of a novel biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: 5-year outcomes of the randomized BIOFLOW-II trial. JACC Cardiovasc Interv. 2018;11(10):995–1002.
   PubMed Web of Science ®Google Scholar
• Paradies V, Vlachojannis GJ, Royaards KJ, et al. Abluminal biodegradable polymer biolimus-eluting versus durable polymer everolimus-eluting stent in patients with diabetes mellitus: 5 years follow-up from the COMPARE II trial. Int J Cardiol. 2019;290:40–44.
   PubMed Web of Science ®Google Scholar
• Jeger RV, Farah A, Ohlow MA, et al., Drug-coated balloons for small coronary artery disease (BASKET-SMALL 2): an open-label randomised non-inferiority trial. Lancet. 392(10150): 849–856. 2018.
   PubMed Web of Science ®Google Scholar
• Giannini F, Latib A, Ancona MB, et al. A propensity score matched comparative study between paclitaxel-coated balloon and everolimus-eluting stents for the treatment of small coronary vessels. Catheter Cardiovasc Interv. 2017;90(3):380–386.
   PubMed Web of Science ®Google Scholar
• Neumann FJ, Sousa-Uva M, Ahlsson A, et al. ESC/EACTS guidelines on myocardial revascularization. Eur Heart J. 2018 [2019];40(2):87–165.
   Web of Science ®Google Scholar
• Ibanez B, James S, Agewall S, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2017 [2018];39(2):119–177.
   Web of Science ®Google Scholar
• Mauri L, Hsieh WH, Massaro JM, et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med. 2007;356(10):1020–1029.
   PubMed Web of Science ®Google Scholar
• Mauri L, Kereiakes DJ, Yeh RW, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014;371(23):2155–2166.
   PubMed Web of Science ®Google Scholar
• Hermiller JB, Krucoff MW, Kereiakes DJ, et al., Benefits and risks of extended dual antiplatelet therapy after Everolimus-Eluting Stents. JACC Cardiovasc Interv. 9(2): 138–147. 2016.
   PubMed Web of Science ®Google Scholar
• Palmerini T, Benedetto U, Bacchi-Reggiani L, et al. Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials. Lancet. 2015;385(9985):2371–2382.
   PubMed Web of Science ®Google Scholar
• Navarese EP, Andreotti F, Schulze V, et al. Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials. BMJ. 2015;350:1–12.
   Google Scholar
• Natsuaki M, Morimoto T, Yamamoto E, et al. One-year outcome of a prospective trial stopping dual antiplatelet therapy at 3 months after everolimus-eluting cobalt-chromium stent implantation: shortt and optimal duration of dual antiplatelet therapy after everolimus-eluting cobalt-chromium stent (ST. Cardiovasc Interv Ther. 2016;31(3):196–209.
   PubMed Web of Science ®Google Scholar
• Watanabe H, Domei T, Morimoto T, et al. Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial. J Am Med Assoc. 2019;321(24):2414–2427.
   PubMed Web of Science ®Google Scholar
• Généreux P, Rutledge DR, Palmerini T, et al. Stent thrombosis and dual antiplatelet therapy interruption with everolimus-eluting stents: insights from the Xience v coronary stent system trials. Circ Cardiovasc Interv. 2015;8(5):1–10.
   Web of Science ®Google Scholar
• Gilard M, Barragan P, Noryani AAL, et al. 6-versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial. J Am Coll Cardiol. 2015;65(8):777–786.
   PubMed Web of Science ®Google Scholar
• Shinke T, Itoh T, Ishida M, et al. Early and mid-term vascular responses to optical coherence tomography–guided everolimus-eluting stent implantation in stable coronary artery disease. Can J Cardiol. 2019;35(11):1513–1522.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov [Internet]. Identifier NCT03355742. XIENCE 28 global study. [Cited 2020 Apr 07]. Available from: https://clinicaltrials.gov/ct2/show/NCT03355742?cond=xience+28&draw=2&rank=2.
   Google Scholar
• ClinicalTrials.gov [Internet]. Identifier NCT03218787. XIENCE 90: a safety evaluation of 3-month DAPT after XIENCE implantation for HBR Patients. [Cited 2020 Apr 07]. Available from: https://clinicaltrials.gov/ct2/show/NCT03218787?cond=xience+90&draw=2&rank=1.
   Google Scholar
• Diletti R, Serruys PW, Farooq V, et al. ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatm. Am Heart J. 2012;164(5):654–663.
   PubMed Web of Science ®Google Scholar
• Serruys PW, Chevalier B, Sotomi Y, et al. Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial. Lancet. 2016;388(10059):2479–2491.
   PubMed Web of Science ®Google Scholar
• Stone GW, Ellis SG, Gori T, et al. Blinded outcomes and angina assessment of coronary bioresorbable scaffolds: 30-day and 1-year results from the ABSORB IV randomised trial. Lancet. 2018;392(10157):1530–1540.
   PubMed Web of Science ®Google Scholar
• Santulli G, Wronska A, Uryu K, et al. A selective microRNA-based strategy inhibits restenosis while preserving endothelial function. J Clin Invest. 2014;124(9):4102–4114.
   PubMed Web of Science ®Google Scholar